Reversible Electroporation-Mediated Liposomal Doxorubicin Delivery to Tumors Can Be Monitored With 89Zr-Labeled Reporter Nanoparticles. Academic Article uri icon

Overview

abstract

  • Reversible electroporation (RE) can facilitate nanoparticle delivery to tumors through direct transfection and from changes in vascular permeability. We investigated a radiolabeled liposomal nanoparticle (89Zr-NRep) for monitoring RE-mediated liposomal doxorubicin (DOX) delivery in mouse tumors. Intravenously delivered 89Zr-NRep allowed positron emission tomography imaging of electroporation-mediated nanoparticle uptake. The relative order of 89Zr-NRep injection and electroporation did not result in significantly different overall tumor uptake, suggesting direct transfection and vascular permeability can independently mediate deposition of 89Zr-NRep in tumors. 89Zr-NRep and DOX uptake correlated well in both electroporated and control tumors at all experimental time points. Electroporation accelerated 89Zr-NRep and DOX deposition into tumors and increased DOX dosing. Reversible electroporation-related vascular effects seem to play an important role in nanoparticle delivery to tumors and drug uptake can be quantified with 89Zr-NRep.

publication date

  • January 1, 2018

Research

keywords

  • Doxorubicin
  • Drug Delivery Systems
  • Electroporation
  • Nanoparticles
  • Neoplasms
  • Radioisotopes
  • Radiopharmaceuticals
  • Zirconium

Identity

PubMed Central ID

  • PMC5833236

Scopus Document Identifier

  • 85054848224

Digital Object Identifier (DOI)

  • 10.1177/1536012117749726

PubMed ID

  • 29480077

Additional Document Info

volume

  • 17